You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Discover a new possible™
We are Dedicated
To advancing AF treatment through focusing on three main areas: innovating new technology solutions, investing in research and publications to advance clinical understanding and improving education and awareness of AF among clinicians and the general public.
For over 20 years, we have been deeply committed to delivering innovative solutions designed to help clinicians reach more patients and heal more hearts.
Research & Publications
With approximately 150 electrophysiology centres globally and a heritage of pioneering treatment in the field of EP, we are committed to advancing quality of care.
Atrial Fibrillation is fast becoming one of the world’s most significant public health issues – affecting 14 millions of lives across EMEA and placing a critical burden on healthcare systems 1-3
27 October 2020
Comparing the Effectiveness of Different Catheter Ablation Technologies to Help Atrial Fibrillation (AF) Patients Live ‘Disease Free’
27 August 2020
Biosense Webster Launches CARTO® 3 System Version 7 and the CARTO PRIME™ Mapping Module to Advance Treatment of Complex Arrhythmias
1. Zoni-Berisso M., L. C. D. (2014). Epidemiology of atrial fibrillation: European perspective.
Clinical Epidemiology 2014:6:213-220.
2. Ball et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st Century. International Journal of Cardiology 167 (2013) 1807–1824.
3. Data extracted by Global Burden Disease (GBD) Results Tool - GHDx website 24/10/2017
This site is published by Johnson & Johnson Medical NV/SA which is solely responsible for its content.
The minimum age for the website is 18. This site is intended for Healthcare Professionals from Europe, Middle-East and Africa where English is accepted in accordance with local laws and regulations, if applicable.
Important Information: Prior to use, refer to the “instructions for use” supplied with these devices for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of the Biosense Webster policy of continuous product development we reserve the right to change product specifications without prior notification.
Always verify catheter tip location using fluoroscopy or IC signals and consult the CARTO® 3 System User Guide regarding recommendations for fluoroscopy use.* Catheter advancement should be done under fluoroscopic guidance. Do not use excessive force to advance or withdraw the catheter when resistance is encountered. Careful catheter manipulation must be performed in order to avoid cardiac damage, perforation, or tamponade.
*Sporton S, Earley M, Nathan A, and Schilling R, Electroanatomic versus fluoroscopic mapping for catheter ablation procedures: A prospective randomized study. Journal of Cardiovascular Electrophysiology 2004;15,3:310-315
Product availability may differ in each country. Please contact us to find out further information.
Third party trademarks used herein are trademarks of their respective owners.
For full product details and precautions, please consult the IFU.
This publication is not intended for distribution outside of the EMEA region.
© Johnson & Johnson Medical NV/SA 2020. All rights reserved.
This site is published by Johnson & Johnson Medical NV/SA, which is solely responsible for its content.
This site is for visitors from Europe, Middle East and Africa.
The third party trademarks used herein are trademarks of their respective owners.